| Controlled substance | Drug code | Schedule |
|---|---|---|
| Cocaine | 9041 | II |
| Codeine | 9050 | II |
| Dihydrocodeine | 9120 | II |
| Oxycodone | 9143 | II |
| Hydromorphone | 9150 | II |
| Diphenoxylate | 9170 | II |
| Ecgonine | 9180 | II |
| Hydrocodone | 9193 | II |
| Meperidine | 9230 | II |
| Methadone | 9250 | II |
| Methadone intermediate. | 9254 | II |
| Morphine | 9300 | II |
| Thebaine | 9333 | II |
| Opium tincture | 9630 | II |
| Oxymorphone | 9652 | II |
| Noroxymorphone | 9668 | II |
| Alfentanil | 9737 | II |
| Remifentanil | 9739 | II |
| Sufentanil | 9740 | II |
| Tapentadol | 9780 | II |
| Fentanyl | 9801 | II |

In reference to drug codes 7360 (Marijuana), and 7370 (THC), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Dated: February 11, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–02882 Filed 2–20–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–392]**

### Bulk Manufacturer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted a registration by the Drug Enforcement Administration (DEA) as a bulk manufacturer of various classes of schedule I and II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as a bulk manufacturer of various basic classes of controlled substances. Information on the previous published notice are listed in the table below. No comments or objections were submitted for this notice.

| Company | FR docket | Published |
|---|---|---|
| Sigma Aldrich Research. | 83 FR 54613 | October 30, 2018. |

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a registration as a bulk manufacturer to the above listed company.

Dated: January 29, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–02869 Filed 2–20–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–392]**

### Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrant listed below has applied for and has been granted registration by the Drug Enforcement Administration (DEA) as an importer of schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The company listed below applied to be registered as an importer of a basic class of controlled substance. Information on the previously published notice is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for this notice.

| Company | FR docket | Published |
|---|---|---|
| Myoderm | 83 FR 66751 | December 27, 2018. |

The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrant to import the applicable basic class of schedule II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule II controlled substances to the above listed company.

Dated: February 11, 2019.

**John J. Martin,**

*Assistant Administrator.*

[FR Doc. 2019–02870 Filed 2–20–19; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–392]**

### Importer of Controlled Substances Registration

**ACTION:** Notice of registration.

**SUMMARY:** The registrants listed below have applied for and been granted registration by the Drug Enforcement Administration (DEA) as importers of schedule I or schedule II controlled substances.

**SUPPLEMENTARY INFORMATION:** The companies listed below applied to be registered as importers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices.

| Company | FR docket | Published |
|---|---|---|
| Janssen Pharmaceuticals, Inc | 83 FR 58598 | November 20, 2018. |
| Lipomed | 83 FR 58601 | November 20, 2018. |
| Akorn, Inc | 83 FR 60896 | November 27, 2018. |
| Cambridge Isotope Laboratories | 83 FR 60897 | November 27, 2018. |
| GE Healthcare | 83 FR 60899 | November 27, 2018. |
| Fisher Clinical Services, Inc | 83 FR 60900 | November 27, 2018. |